Fig. 11.1 Periodic table For the bone-targeted radiopharmaceuticals such as Sm-153 EDTMP, strontium-89 (Sr-89), radium-223 (Ra-223), and phosphorus-32 (P-32), as well as the bisphosphonates, bone targeting occurs via hydroxyapatite Ca5(PO4)3(OH)…

Fig. 18.1 The principle of synthetic lethality applied to cancer medicine. While the loss of either PARP or BRCA function independently does not compromise the ability of the cell to…

Fig. 1.1 Management-based dynamic progression of prostate cancer and the mCRPC state. ADT androgen deprivation treatment Fig. 1.2 Survival of metastatic prostate cancer patients diagnosed in the context of a…

PROM name Use What has it shown? Comment Authors or reference General PROMs Medical outcomes study short-form health survey (SF-36 and SF-12) Studies of populations with multiple diseases Hard to…

Fig. 6.1 The androgen receptor pathway and novel targeted agents The activated AR can also function as a transcription repressor through its antagonistic interaction with transcription factors (e.g., specificity protein…

Persistent AR signaling Stress response pathways Signaling pathways Developmental pathways AR, N-Terminal AR, co-factors LSD-1 and BF3 Hsp27, CLU, autophagy, Hsp90, p38 MAPK PI3K/Akt, MAPK, JNK, NF-κB, CCL2, MET, src…

Castrate-resistant a prostate carcinoma with at least 1 of the following: C1. Histologic evidence of small-cell prostate carcinoma (pure or mixed) C2. Exclusively visceral metastases C3. Radiographically predominant lytic bone…

Fig. 13.1 A pharmacologic audit trail for clinical trial design. Solid boxes contain the conceptualized trial framework; dashed boxes demonstrate the example of a new therapy targeting androgen receptor (AR)…

Fig. 8.1 Proposed model of taxane mechanism of action in prostate cancer. AR associates with microtubules and translocates to the nucleus via the motor protein dynein. Taxanes inhibit depolymerization of…